drugset
drugset / Trial / NCT07174492

Efficacy and Safety of Masitinib in Combination With SoC Versus Placebo in the Treatment of ALS Patients

NCT07174492 ↗

Phase 3 Not yet recruiting 412 enrolled AB Science
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The objective is to compare the efficacy and safety of masitinib in combination with riluzole versus matched placebo in combination with riluzole for the treatment of Amyotrophic Lateral Sclerosis (ALS).

Timeline

Start
2026-01-01
Primary completion
2028-12-31
Completion
2029-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Masitinib Small molecule 4.5 mg/kg Oral
Background Riluzole Small molecule 50 mg Oral

Indications

amyotrophic lateral sclerosis